April 25, 2025 07:43 AM EDT

AbbVie's immunology franchise remains a powerhouse, as Skyrizi, Rinvoq combine for $5B

Max Gelman

Senior Editor

One quarter after AbbVie raised future sales estimates due to the successes of its immunology portfolio, the company again saw higher-than-expected revenues …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AbbVie's immunology franchise remains a powerhouse, as Skyrizi, Rinvoq combine for $5B

Max Gelman

Senior Editor

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

New fund will pressure flailing biotechs, as investor frustration boils over

Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient

Paul Stoffels on retiring from Galapagos; Boehringer Ingelheim switches up leadership

Merck KGaA closes in on SpringWorks deal at $3.5B price point

Merck cuts several Phase 2 programs; Vyne’s Phase 1b psoriasis trial put on clinical hold

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Ab­b­Vie's im­munol­o­gy fran­chise re­mains a pow­er­house, as Skyrizi, Rin­voq com­bine for $5B

Senior Editor

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

AbbVie's immunology franchise remains a powerhouse, as Skyrizi, Rinvoq combine for $5B